Medical/Pharmaceuticals
HELP Therapeutics and China Resources Sanjiu Announce Strategic Partnership to Co-Develop and Commercialize HiCM-188 for Advanced Heart Failure in Mainland China
NANJING, China, June 16, 2025 /PRNewswire/ -- HELP Therapeutics, a global leader in regenerative medicine, and China Resources Sanjiu Pharmaceutical Company, one ofChina's largest pharmaceutical companies, have announced a strategic partnership to co-develop and commercialize the investigational ...
2025-06-16 22:40
2695
Global Action to End Smoking Welcomes Nataliia Toropova as Chief Development Officer
Toropova brings decades of experience in international public health and tobacco harm reduction to Global Action's team of experts committed to funding work to end the smoking epidemic. NEW YORK, June 16, 2025 /PRNewswire/ -- Global Action to End Smoking is pleased to announce the appointment...
2025-06-16 22:00
2314
A Decade of Persistent Steps, Aspiring for a Thousand Miles: Qyuns' Grand 10th Anniversary Celebration Held Successfully
TAIZHOU, China, June 16, 2025 /PRNewswire/ -- A Decade of Persistent Steps, Aspiring for a Thousand Miles! From June 13th to 14th, 2025, Qyuns' 10th Anniversary Celebration was successfully held in Taizhou. All employees of Qyuns, along with representatives from research institutions, industry p...
2025-06-16 21:14
2491
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
* Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma * Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 * Partnership leverages stra...
2025-06-16 21:03
2226
American Migraine Foundation Highlights HeadaTerm2 in Its Latest Device Recommendations, Backed by Clinical Evidence
VANCOUVER, BC, June 16, 2025 /PRNewswire/ -- WAT Medical Enterprise Ltd. is pleased to announce that its migraine relief device, HeadaTerm 2, is now featured on the American Migraine Foundation's (AMF) updated Device Corner, a patient education resource highlighting FDA-cleared neuromodulation de...
2025-06-16 21:00
1925
China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, June 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced key developments...
2025-06-16 20:33
1885
BioDlink's Bevacizumab Approved for Market Launch in Nigeria, Accelerating Global Expansion
* BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) , followingGMP certifications in Brazil (a PIC/S member), Colombia, Egypt, Indonesia, and Argentina—further strengthening its global prese...
2025-06-16 20:30
1742
"Luminous Path, Shared Stride - Brazil and China"
SHANGHAI, June 16, 2025 /PRNewswire/ -- Brazil's HIHUB.TECH delegation embarked on a landmark visit toShanghai, exploring cutting-edge advancements in healthcare and aesthetic medicine. The delegation's first stop was Zhongshan Hospital, a world-renowned medical institution consistently ranke...
2025-06-16 20:08
1467
WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors
SHANGHAI, June 16, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been recognized among the Top 10 "Most Honored Companies" in new rankings from Extel ...
2025-06-16 20:00
1915
Flat Medical Partners with Mercury Medical for US Distribution of EpiFaith Smart Syringe
Strategic Partnership Brings Breakthrough Epidural Safety Technology to US Anesthesia Market AUSTIN, Texas, June 16, 2025 /PRNewswire/ -- Flat Medical, a pioneering medtech company specializing in innovative safety solutions for anesthesia and pain medicine, today announced it has signed a deale...
2025-06-16 20:00
1513
PATHOLOGICAL COMPLETE RESPONSE RECORDED IN PATIENT FROM ACCENT CANCER TRIAL
HIGHLIGHTS * A confirmed pathological complete response has been recorded in the ACCENT trial * A pathological complete response (pCR) is extremely rare in patients undergoing treatment for advanced pancreatic cancer * A pCR means that there are no signs of cancer in tissue examined by a p...
2025-06-16 19:00
1564
NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
Highlights: * NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease * Treatment prevented hallmark developmental and morphological abnormalities, protected against neuronal cell death, restored delayed h...
2025-06-16 19:00
1843
8th Asia Dengue Summit Renews Call to Achieve Zero Dengue Deaths, with a Record 14 million Global Cases Reported in 2024
Health leaders, researchers, and advocates unite to advance efforts against dengue through innovation, prevention, and cross-sector collaboration. MANILA, Philippines, June 16, 2025 /PRNewswire/ -- As dengue cases in 2024 double to over 14 million globally, with Asia accounting for 70% of the gl...
2025-06-16 17:35
2558
Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology
New Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted Innovation and Strategic Growth LONDON, June 16, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announce...
2025-06-16 16:00
1670
Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC") CASTRES, France, June 16, 2025 /PRNewswire/ -- Pierre Fabre Laboratories are pleased to announc...
2025-06-16 16:00
1877
NX Malaysia Opens New Batu Kawan Logistics Center near Penang's Batu Kawan Industrial Park
-Nearly 10,000m2 of Warehouse Space Available for Semiconductor, Medical Equipment and Other Companies- TOKYO, June 16, 2025 /PRNewswire/ -- Nippon Express (Malaysia) Sdn, Bhd. (hereafter "NX Malaysia"), a group company of NIPPON EXPRESS HOLDINGS, INC., held a completion ceremony on May 27 to m...
2025-06-16 15:00
1732
Hasten Accelerates Asia-Pacific Expansion with Successful MAT Transfers of 11 Products
SHANGHAI, June 16, 2025 /PRNewswire/ -- Hasten Biopharmaceutical Co., Ltd. ("Hasten") announced today the completion of Market Authorization Transfers (MAT) for 11 major pharmaceutical products across several key Asia-Pacific markets, including Malaysia, Singapore, Philippines, Hong Kong S.A.R. (...
2025-06-16 12:29
2450
The 4th Edition of AMSC Malaysia Returns in 2025: Uniting Global Leaders in Aesthetic Medicine, Dermatology, and Surgery
KUALA LUMPUR, Malaysia, June 16, 2025 /PRNewswire/ -- The Aesthetic Medicine &
Surgery Conference & Exhibition (AMSC)
2025-06-16 11:30
2147
Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China
SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
2025-06-16 10:56
2416
Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC
SHANGHAI, June 16, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of irpagratinib, a self-developed and highly-selective small molecule FGFR4 inhibitor, for the treatment of Hepatocellular Carcinoma...
2025-06-16 10:47
1875
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 264 media titles]
2026-01-01 10:00
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 263 media titles]
2025-12-29 09:00
